{"id":692298,"date":"2022-10-05T08:04:11","date_gmt":"2022-10-05T12:04:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/"},"modified":"2022-10-05T08:04:11","modified_gmt":"2022-10-05T12:04:11","slug":"codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/","title":{"rendered":"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\u2013 Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting \u2013<\/p>\n<p align=\"left\">CAMBRIDGE, Mass., Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that two posters featuring preclinical data from its engEx\u00ae Platform programs will be presented during the 37<sup>th<\/sup> Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), which is being held in Boston from November 8-12, 2022.<\/p>\n<p align=\"left\">\u201cAt SITC, we will present new preclinical data on two of our systemically administered exosome therapeutic candidates which target macrophages and have previously demonstrated potent monotherapy activity in preclinical models,\u201d said Sriram Sathyanarayanan, Ph.D., Codiak\u2019s Chief Scientific Officer. \u201cBoth exoASO\u2122-STAT6 and exoASO\u2122-C\/EBP\u03b2 specifically inhibit transcription factors in distinct macrophage subpopulations by leveraging engineered exosomes to selectively target pathways known to play a critical role in tumor immunology.\u201d<\/p>\n<p align=\"left\">\n        <strong><br \/>\n          <u>Poster Presentations:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Title: Preclinical PK\/PD profile, biomarker identification and rationale for indication selection of exoASO\u2122-STAT6, a selective tumor-associated macrophage targeting candidate<\/strong><br \/>\n        <br \/>Abstract number: 1344<br \/>Date: Friday, November 11, 2022<\/p>\n<p align=\"left\">\n        <strong>Title: exoASO\u2122-C\/EBP\u03b2: An engineered exosome therapeutic that selectively targets MDSCs and induces potent single-agent anti-tumor activity in checkpoint refractory tumor models<\/strong><br \/>\n        <br \/>Abstract number: 1345<br \/>Date: Thursday, November 10, 2022<\/p>\n<p align=\"left\">Abstracts will be made available by SITC on November 7, 2022, at 8:00 a.m. ET and posters will be available via the conference platform beginning November 10, 2022, at 9:00 a.m. ET. The posters may be accessed on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1sJOp5bLk6EmcDAfqiha9k23ZLEV1kWPnBR2BQH5lVGgLi5-GNcTJeN5YeDumxix7Vjs1WxUK5qEw_gZIvolU2qovmDE-sxxoJjH7EL9DIicsTSHXjv8HTpORY-qX7R0VWNMrucdAZM7Rt4UV_e7Fg==\" rel=\"nofollow noopener\" target=\"_blank\">Publications &amp; Presentations<\/a> page of the Codiak website following presentation.<\/p>\n<p align=\"left\">\n        <strong>About exoASO\u2122-STAT6 and exoASO\u2122-C\/EBP\u03b2<\/strong><br \/>\n        <br \/>Codiak\u2019s exoASO-STAT6 is an engineered exosome investigational therapeutic candidate designed to selectively deliver antisense oligonucleotides (ASOs) to disrupt STAT6 signaling in tumor associated macrophages (TAMs) and induce an anti-tumor immune response. exoASO-STAT6 is Codiak\u2019s third clinical program and the first to evaluate a systemically administered exosome-based drug candidate. A Phase I clinical trial evaluating exoASO-STAT6 in patients with advanced hepatocellular carcinoma, liver metastases from primary gastric cancer and colorectal cancer is underway.<\/p>\n<p align=\"left\">Codiak\u2019s exoASO-C\/EBP\u03b2 is designed to selectively deliver ASOs to down-modulate C\/EBP\u03b2, a transcription factor that regulates the immunosuppressive phenotype in TAMs and circulating myeloid derived suppressor cells (MDSCs), two sub-populations of myeloid cells. High levels of C\/EBP\u03b2 expression are associated with poor prognosis in multiple cancers, including non-small cell lung cancer (NSCLC).<\/p>\n<p align=\"left\">\n        <strong>About Codiak BioSciences <\/strong><br \/>\n        <br \/>Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx\u00ae Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx\u00ae Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, infectious disease and rare disease.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of Codiak\u2019s investigational candidates, including statements concerning the clinical development of exoASO-STAT6, and statements regarding the capabilities and potential of Codiak\u2019s engEx Platform and engineered exosomes generally. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. In particular, the statements regarding the initiation and timing of clinical trials are dependent upon availability of sufficient cash resources, as to which the Company can make no assurance. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in Codiak\u2019s Annual Report on Form 10-K for the year ended December 31, 2021, and in subsequent filings with the Securities and Exchange Commission (SEC), as well as discussions of potential risks, uncertainties and other important factors in Codiak\u2019s subsequent filings with the SEC. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Christopher Taylor<br \/>VP, Investor Relations and Corporate Communications <br \/>T: 617-949-4220<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ApQYiCuc25qRsfgZyImMq5YnIxIANRwIJPYESpONDwCUh23zK5FS4FyKMo-zLYn-oOUP6EgTf6-vPJC0BwbeTks8oOrLKdltZW0fbnyAM4g=\" rel=\"nofollow noopener\" target=\"_blank\">investor@codiakbio.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Cory Tromblee<br \/>Scient PR<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-xs5gqVNPfB5nydrV6pmQRuV17S0T7e0mETzMAMykJ7Bf5oe87tVJX5HoNTTTqJ9pNneP0YZn6hfYXqMXEa49kkP2EwOEs1m7b_rAqFEkWQ=\" rel=\"nofollow noopener\" target=\"_blank\">media@codiakbio.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTA2MmI3MmQtOTg5Mi00NWRjLThmNTgtYjdkOTYxYzc2ZDA1LTExNjg1NzI=\/tiny\/Codiak-BioSciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting \u2013 CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that two posters featuring preclinical data from its engEx\u00ae Platform programs will be presented during the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), which is being held in Boston from November 8-12, 2022. \u201cAt SITC, we will present new preclinical data on two of our systemically administered exosome therapeutic candidates which target macrophages and have previously demonstrated potent monotherapy activity in preclinical models,\u201d said Sriram Sathyanarayanan, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692298","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting \u2013 CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that two posters featuring preclinical data from its engEx\u00ae Platform programs will be presented during the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), which is being held in Boston from November 8-12, 2022. \u201cAt SITC, we will present new preclinical data on two of our systemically administered exosome therapeutic candidates which target macrophages and have previously demonstrated potent monotherapy activity in preclinical models,\u201d said Sriram Sathyanarayanan, &hellip; Continue reading &quot;Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages\",\"datePublished\":\"2022-10-05T12:04:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/\"},\"wordCount\":779,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/\",\"name\":\"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=\",\"datePublished\":\"2022-10-05T12:04:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/","og_locale":"en_US","og_type":"article","og_title":"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages - Market Newsdesk","og_description":"\u2013 Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting \u2013 CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that two posters featuring preclinical data from its engEx\u00ae Platform programs will be presented during the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), which is being held in Boston from November 8-12, 2022. \u201cAt SITC, we will present new preclinical data on two of our systemically administered exosome therapeutic candidates which target macrophages and have previously demonstrated potent monotherapy activity in preclinical models,\u201d said Sriram Sathyanarayanan, &hellip; Continue reading \"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:04:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages","datePublished":"2022-10-05T12:04:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/"},"wordCount":779,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/","name":"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=","datePublished":"2022-10-05T12:04:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA4MSM1MTg3ODgzIzIxNTcwMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-new-preclinical-data-demonstrating-potent-monotherapy-activity-of-two-engineered-exosome-intravenous-candidates-targeting-macrophages\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity\u00a0of Two Engineered Exosome Intravenous Candidates Targeting Macrophages"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692298"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692298\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}